MW
VRTX icon

Milestone Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Milestone Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-110
Closed -$24K – 250
2022
Q1 		$24K Hold
110
– – 0.02% 172
2021
Q4 		$24K Buy
+110
New +$21.4K 0.02% 172

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Milestone Wealth's VRTX Position: Q2 2022 in Review

Milestone Wealth sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 110 shares — an estimated $24K sold.

Milestone Wealth first reported a position in VRTX in Q4 2021 and held it in 2 quarters. The position peaked at $24K in Q1 2022. 1,108 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Milestone Wealth reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Milestone Wealth sold 110 Vertex Pharmaceuticals shares in Q2 2022, an estimated $24K.
  • Milestone Wealth first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Milestone Wealth's Vertex Pharmaceuticals position peaked at $24K in Q1 2022.
  • 1,108 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Milestone Wealth's 13F filing for Q2 2022, filed 12 Aug 2022.